Identifying biomarkers to predict cognitive decline after radiation therapy for brain tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate systemic biomarkers in pediatric and young adult patients with brain tumors who are undergoing radiotherapy. It will involve collecting biological samples, including peripheral blood and cerebrospinal fluid, at various stages of treatment and follow-up. The study will analyze these samples for markers of neuroinflammation and other factors that may contribute to cognitive decline post-radiation. By understanding these biomarkers, the study seeks to improve the quality of life for patients by potentially mitigating long-term neurocognitive side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 5-39 years
2. Histological diagnosis of primary brain tumor
3. Decision for treatment with radical intent radiotherapy
4. Signed assent and parental consent form for pediatric age group and signed consent form for adults.

Exclusion Criteria:

1. Inability to undergo neurocognitive evaluation
2. Palliative radiotherapy.
3. Expected life expectancy \< 1 year

Where it's running

• Tata Memorial Hospital (TMH) Parel, and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Kharghar
  Mumbai, Maharashtra, India Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pharmacoscopy-guided treatment for refractory brain tumors

  This trial tests whether personalized drug testing on a patient’s tumor cells can guide treatment choices for adults with hard-to-treat brain cancers like glioblastoma.

  Recruiting Phase 2 University of Zurich · Basel, Basel-Landschaft and 2 other locations · NCT06804655

• Testing PLX038 for brain and spinal cord tumors with MYC or MYCN amplifications

  This study is testing a new treatment called PLX038 for adults with brain and spinal cord tumors that have specific gene changes to see if it helps improve their condition.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06161519

• Investigating genetic and molecular profiles of pediatric brain tumors in China

  This study is trying to understand the genetic makeup of brain tumors in children to see how it affects their treatment and recovery.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT05672043

• B7-H3 CAR T cells for recurrent brain tumors in kids and young adults

  This early-phase trial tests a personalized CAR T-cell therapy called B7-H3 CAR T for children and young adults with recurrent or progressive brain tumors.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07390539

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

• Observational assessment of treatment outcomes for patients with primary brain tumors

  This study looks at how well treatments work for people with rare primary brain tumors using new classification guidelines to see if they help doctors group patients better.

  Recruiting at 42 sites European Organisation for Research and Treatment of Cancer - EORTC · Innsbruck and 41 other locations · NCT05259605

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.